Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityVTVT / vTv Therapeutics Inc (918385105)
President & CEOHolcombe Stephen L.
IndustryPharmaceutical Preparations
Institutional Owners49
Institutional Shares5,697,347 - 24.67%
Common Shares Outstanding223,094,221 shares (as of 2018-03-31)
Institutional Value$ 29,108,000 USD

Institutional Stock Ownership and Shareholders()

VTVT / vTv Therapeutics Inc Institutional Ownership

vTv Therapeutics Inc (NASDAQ:VTVT) has 49 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,697,347 shares. Largest shareholders include GMT Capital Corp, Franklin Resources Inc, Massachusetts Financial Services Co /ma/, Royce & Associates LLC, BlackRock Inc., JP Morgan Chase & Co, FMR LLC / Fidelity, Vanguard Group Inc, Sphera Funds Management Ltd., and BlackRock Fund Advisors.
vTv Therapeutics Inc (NASDAQ:VTVT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/vtvt"><img src="https://images.fintel.io/us-vtvt-so.png" alt="VTVT / vTv Therapeutics Inc Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-10 13F-HR SPHERA FUNDS MANAGEMENT LTD. 281,679 281,679 0.00 1,693 1,146 -32.31
2018-05-11 13F-HR CITIGROUP INC 715 0 -100.00 4 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 1,539 1,555 1.04 9 6 -33.33
2018-05-15 13F-HR VANGUARD GROUP INC 226,097 293,550 29.83 1,359 1,194 -12.14
2018-05-15 13F-HR STATE STREET CORP 111,724 104,241 -6.70 673 424 -37.00
2018-05-10 13F-HR FRANKLIN RESOURCES INC 850,100 835,323 -1.74 5,109 3,400 -33.45
2018-05-14 13F-HR MORGAN STANLEY 32,474 32,709 0.72 195 133 -31.79
2017-02-10 13F-HR BlackRock Investment Management, LLC 27,758 27,758 0.00 200 134 -33.00
2018-05-09 13F-HR Candriam Luxembourg S.C.A. 90,000 0 -100.00 541 0 -100.00
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 4,300 4,300 0.00 26 18 -30.77
2018-05-15 13F-HR UBS Group AG 714 1,000 40.06 4 4 0.00
2018-05-17 13F-HR Legal & General Group Plc 888 888 0.00 5 4 -20.00
2018-05-15 13F-HR Advisor Group, Inc. 800 1,200 50.00 5 5 0.00
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 5,117 4,860 -5.02 31 20 -35.48
2018-05-15 13F-HR/A Sabby Management, LLC 44,500 0 -100.00 267 0 -100.00
2018-05-15 13F-HR Bank of New York Mellon Corp 21,973 21,973 0.00 132 90 -31.82
2018-05-14 13F-HR FMR LLC / Fidelity 0 295,838 0 1,204
2018-05-14 13F-HR Perigon Wealth Management, LLC 75 75 0.00 0 0
2018-05-10 13F-HR JP Morgan Chase & Co 210,215 327,728 55.90 1,263 1,333 5.54
2018-05-15 13F-HR DEUTSCHE BANK AG\ 16,536 28,284 71.04 99 114 15.15
2017-02-10 13F-HR BlackRock Fund Advisors 213,273 245,203 14.97 1,533 1,184 -22.77
2018-05-15 13F-HR BALYASNY ASSET MANAGEMENT LLC 24,200 98
2017-01-18 13F-HR WALL STREET ASSOCIATES 244,000 164,939 -32.40 1,754 797 -54.56
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 11,218 11,218 0.00 67 46 -31.34
2016-12-28 SC 13G/A PIPER JAFFRAY COMPANIES 685,995 181,910 -73.48
2018-05-03 13F-HR BRONFMAN E.L. ROTHSCHILD, L.P. 29 29 0.00 0 0
2018-05-14 13F-HR Renaissance Technologies LLC 55,000 19,800 -64.00 331 81 -75.53
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 39 39 0.00 0 0
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 62,669 95,031 51.64 377 387 2.65
2018-05-14 13F-HR Royce & Associates LLC 225,000 363,000 61.33 1,352 1,477 9.25
2018-05-09 13F-HR NORTHERN TRUST CORP 77,026 96,200 24.89 463 391 -15.55
2017-02-10 13F-HR BlackRock Advisors LLC 48,892 48,892 0.00 352 236 -32.95
2018-05-15 13F-HR BARCLAYS PLC 2,063 2,083 0.97 13 8 -38.46
2018-04-18 13F-HR Creative Planning 19,000 0 -100.00 114 0 -100.00
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 500 500 0.00 3 2 -33.33
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 41,949 43,691 4.15 252 177 -29.76
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 1,294 5,817 349.54 8 24 200.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 829 541 -34.74 5 2 -60.00
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 1,735 1,528 -11.93 10,427 6,219 -40.36
2018-05-15 13F-HR Alyeska Investment Group, L.P. 189,143 53,955 -71.47 1,137 220 -80.65
2018-05-09 13F-HR BlackRock Inc. 344,317 341,986 -0.68 2,070 1,392 -32.75
2018-05-14 13F-HR TEACHERS ADVISORS INC 8,421 0 -100.00 51 0 -100.00
2018-05-04 13F-HR MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 450,892 455,553 1.03 2,710 1,854 -31.59
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 12,200 12,200 0.00 74 50 -32.43
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 67 10 -85.07 0 0
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 172,924 0 -100.00 1,039 0 -100.00
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 15,064 15,064 0.00 91 61 -32.97
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 2,685 1,186 -55.83 16 5 -68.75
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 1,134 0 -100.00 7 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 91,121 74,280 -18.48 655 359 -45.19
2018-05-15 13F-HR J. Goldman & Co LP 26,000 106
2018-05-03 13F-HR CAM Group Holding A/S 97,963 399
2017-02-10 13F-HR BlackRock Group LTD 32,934 32,934 0.00 237 159 -32.91
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 75,000 75,000 0.00 451 305 -32.37
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 4,778 4,534 -5.11 29 18 -37.93
2018-05-15 13F-HR GMT Capital Corp 939,100 3,822

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

11h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Avoiding The 'Black Hole' Of Disease Development

2018-06-15 seekingalpha
Both large and small concerns continue to see nothing but failure in the Alzheimer's space despite spending billions on development efforts. (442-11)

Week In Review: Alibaba Transfers Assets To Ali Health In $1.4 Billion Deal

2018-06-03 seekingalpha
China's e-commerce giant Alibaba (NYSE:BABA) will transfer Ali JK Nutritional products into its online healthcare subsidiary, Alibaba Health (HK:0241), in exchange for $1.4 billion of Ali Health stock. Ali JK Nutritional sells medical devices, healthcare products, adult products, and healthcare services on Alibaba's Tmall platform. During the 12 months ending March 31, Ali JK generated $3.2 billion in sales from over 3,300 related merchants. (89-1)

Your Daily Pharma Scoop: Madrigal Zooms Ahead, Kitov Gets Approval, Mei Pharma's Results Are Positive

2018-06-01 seekingalpha
A little more than three months ago we extensively covered Madrigal Pharmaceuticals' (NASDAQ:MDGL) MGL-3196. Incidentally in that article we wrote “the last three months have seen gains of more than 230%.” And shareholders would have loved to see the same thing happen in the last three months. But that hasn’t happened. However what has happened is perhaps both more intriguing and interesting at the same time. (58-5)

How Newsoara Bio Is Saving vTv Therapeutics

2018-05-31 247wallst
vTv Therapeutics Inc. (NASDAQ: VTVT) shares saw a massive gain early on Thursday after the firm announced an exclusive licensing agreement with Newsoara Biopharma. This deal is for the rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries. (0-2)

Keeping It Simple On The Short Side

2018-05-11 seekingalpha
Today's Editor's Notes reviews five short ideas that each have a way of keeping it simple. (220-14)

CUSIP: 918385105